{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Parsels LA"],"funding":["NINDS NIH HHS","NCI NIH HHS"],"pagination":["100881"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9918797"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["37"],"pubmed_abstract":["Diffuse intrinsic pontine glioma (DIPG) is a rare but highly lethal pediatric and adolescent tumor located in the pons of the brainstem. DIPGs harbor unique and specific pathological and molecular alterations, such as the hallmark lysine 27-to-methionine (H3K27M) mutation in histone H3, which lead to global changes in the epigenetic landscape and drive tumorigenesis. While fractionated radiotherapy, the current standard of care, improves symptoms and delays tumor progression, DIPGs inevitably recur, and despite extensive efforts chemotherapy-driven radiosensitization strategies have failed to improve survival. Advances in our understanding of the role of epigenetics in the cellular response to radiation-induced DNA damage, however, offer new opportunities to develop combinational therapeut"],"journal":["Neoplasia (New York, N.Y.)"],"pubmed_title":["Developing H3K27M mutant selective radiosensitization strategies in diffuse intrinsic pontine glioma."],"pmcid":["PMC9918797"],"funding_grant_id":["R01 NS124607","U01 CA216449","P30 CA046592","R01 NS119231","K08 CA234416","R50 CA251960","R37 CA258346"],"pubmed_authors":["Koschmann C","Morgan MA","Zhang Q","Parsels LA","Wahl DR"],"additional_accession":[]},"is_claimable":false,"name":"Developing H3K27M mutant selective radiosensitization strategies in diffuse intrinsic pontine glioma.","description":"Diffuse intrinsic pontine glioma (DIPG) is a rare but highly lethal pediatric and adolescent tumor located in the pons of the brainstem. DIPGs harbor unique and specific pathological and molecular alterations, such as the hallmark lysine 27-to-methionine (H3K27M) mutation in histone H3, which lead to global changes in the epigenetic landscape and drive tumorigenesis. While fractionated radiotherapy, the current standard of care, improves symptoms and delays tumor progression, DIPGs inevitably recur, and despite extensive efforts chemotherapy-driven radiosensitization strategies have failed to improve survival. Advances in our understanding of the role of epigenetics in the cellular response to radiation-induced DNA damage, however, offer new opportunities to develop combinational therapeut","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2025-05-18T12:27:04.457Z","creation":"2025-02-19T03:27:13.987Z"},"accession":"S-EPMC9918797","cross_references":{"pubmed":["36724689"],"doi":["10.1016/j.neo.2023.100881"]}}